Natalie Yeadon
Patients/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis
Importance of diversity in pharma and clinical trials
mike.hammerton@pharmaphorum.com
clinical trials, decentralised clinical trials, diversity, impetus, Natalie Yeadon, virtual clinical trials
0 Comment
Deep Dive/ Sales and Marketing/ Views & Analysis/ Views and analysis
Refining digital collaboration
mike.hammerton@pharmaphorum.com
Communications and Commercialisation, covid, Deep Dive, Deep Dive: Communications and Commercialisation, impetus, Natalie Yeadon
0 Comment
Digital/ Views & Analysis/ Views and analysis
Gamification for patient care, medical education, and virtual engagement
Catherine Longworth
digital health, digital therapeutics, gamification, Natalie Yeadon, virtual reality
0 Comment
Digital/ Views & Analysis/ Views and analysis
2021 – The healthcare changes here to stay
mike.hammerton@pharmaphorum.com
2021, COVID-19, mental health, Natalie Yeadon, pandemic, public health, telehealth
0 Comment
Deep Dive/ Digital/ Views & Analysis/ Views and analysis
Virtual meetings: Where are we now and where are we going?
mike.hammerton@pharmaphorum.com
Deep Dive, Deep Dive: Communications 2020, digital engagement, impetus, Natalie Yeadon
0 Comment
Digital/ Views & Analysis/ Views and analysis
10 reasons why virtual collaboration and medical education will persist in the new normal
mike.hammerton@pharmaphorum.com
Impetus Digital, medical education, Natalie Yeadon, virtual conferences, virtual meetings
0 Comment
Digital/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis
Secondary effects of COVID-19 on pharma, healthcare and patients
mike.hammerton@pharmaphorum.com
cancer, diagnosis, Natalie Yeadon, telemedicine
0 Comment
Patients/ Views & Analysis/ Views and analysis
Working with, advocating for, and empowering patients – a holistic view
mike.hammerton@pharmaphorum.com
Natalie Yeadon, patient centricity, patient engagement
0 Comment